AI speeds drug discovery as pharma takes risks in 2026
In 2026, the pharmaceutical sector is moving back into a risk on posture, with AI drug discovery shifting from promise to operational impact and a tightening patent cliff timeline pushing capital towards late stage assets. For researchers and industry professionals, the practical benefit is clear. The next 12 months are likely to bring faster target […]